Rallybio Corporation
RLYB
$14.35
$0.322.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 484.21% | -29.10% | -29.10% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 484.21% | -29.10% | -29.10% | -- | -- |
| Cost of Revenue | -32.13% | -49.72% | -19.95% | -47.65% | -66.18% |
| Gross Profit | 35.80% | 50.50% | 14.16% | 49.59% | 66.42% |
| SG&A Expenses | 0.61% | -27.42% | -4.40% | -25.11% | -42.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.51% | -42.28% | -40.76% | -40.06% | -60.47% |
| Operating Income | 22.82% | 42.61% | 40.96% | 41.35% | 60.65% |
| Income Before Tax | 47.01% | 239.68% | 40.24% | 50.40% | 45.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.01% | 239.68% | 40.24% | 50.40% | 45.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.01% | 239.68% | 40.24% | 50.40% | 45.44% |
| EBIT | 22.82% | 42.61% | 40.96% | 41.35% | 60.65% |
| EBITDA | 22.58% | 42.75% | 41.00% | 41.39% | 60.72% |
| EPS Basic | 47.95% | 238.24% | 41.19% | 54.83% | 50.35% |
| Normalized Basic EPS | 25.77% | 45.41% | 41.19% | 45.35% | 65.19% |
| EPS Diluted | 47.95% | 238.24% | 41.19% | 54.83% | 50.35% |
| Normalized Diluted EPS | 25.77% | 45.41% | 41.19% | 45.35% | 65.19% |
| Average Basic Shares Outstanding | 1.79% | 1.04% | 1.62% | 9.81% | 9.90% |
| Average Diluted Shares Outstanding | 1.79% | 1.04% | 1.62% | 9.81% | 9.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |